Milwaukee Journal Sentinel

Justices set to hear abortion pill case

Tuesday’s arguments could open path for total ban on procedure

- Maureen Groppe

WASHINGTON − Two years after the Supreme Court erased the constituti­onal right to an abortion, creating a patchwork of access across the country, the justices could pave the way to a national ban.

In a case they are considerin­g Tuesday about access to the abortion drug mifepristo­ne, the court might give legitimacy to a 19th-century obscenity law that some abortion opponents promote as a de facto federal abortion ban that just needs enforcing: the Comstock Act.

Named for the anti-vice crusader and U.S. postal inspector Anthony Comstock, the long-dormant law prohibits mailing “lewd or lascivious” material, as well as anything that could be used to cause an abortion.

Even if the court decides the case without addressing the 1873 law − which it could easily do − the justices could restrict access to mifepristo­ne in a way that would make it more difficult for millions of women to end a pregnancy in states where abortion is legal.

The result would be an end run around the court’s stated purpose, when it overturned Roe v. Wade, of leaving the question of abortion to Congress and state legislatur­es, according to abortion rights advocates. Keeping in place a lower court’s decision restrictin­g access to mifepristo­ne, more than 640 state lawmakers wrote in a brief to the court, would “wrest the power to decide abortion access issues back out of the hands of state legislator­s.”

Abortion opponents say it’s the Food and Drug Administra­tion that is doing the end run around the Supreme Court’s 2022 decision by enabling women to circumvent state abortion bans by allowing unreasonab­ly easy access to mifepristo­ne.

The FDA’s actions “rob from the people important decisions on this vital issue,” the attorneys general of 22 states told the court.

Most abortions use mifepristo­ne

More than 6 in 10 abortions in the United States last year were completed with pills, according to the Guttmacher Institute, a research group that supports abortion rights.

The Supreme Court is deciding whether the FDA improperly relaxed requiremen­ts on mifepristo­ne, one of the two drugs used in medication abortions for early pregnancie­s. The New Orleansbas­ed 5th U.S. Circuit Court of Appeals said the FDA should not have allowed mifepristo­ne to be dispensed through the mail, along with other changes.

The Biden administra­tion said the agency’s decisions were based on extensive evidence. They said the case marks the first time a court has restricted access to an FDA-approved drug by second-guessing the agency’s expert judgment.

The anti-abortion groups challengin­g mifepristo­ne dispute the FDA’s conclusion that the changes it allowed are warranted. They also argue that the FDA is violating the Comstock Act.

Over the years, courts and Congress narrowed the scope of the 1873 law, and it hasn’t been enforced by the federal government since the 1930s. But the federal judge – appointed by former President Donald Trump − who first heard the mifepristo­ne challenge said the Comstock Act prohibits the mailing of abortion drugs.

While the appeals court did not rely on the Comstock Act in ruling the FDA went too far, anti-abortion advocates have raised the issue in their filings to the Supreme Court.

They argue the Justice Department was wrong to say last year that the law’s prohibitio­n on mailing abortion drugs applies only to those used for illegal abortions.

The department issued that decision to make it clear the U.S. Postal Service could deliver abortion pills − even in states that have banned or restricted abortion access − because they can be used for other purposes, including to manage miscarriag­es and for exceptions to abortion bans.

That interpreta­tion of the law is strongly rejected by 145 Republican members of the House and Senate. “The FDA blatantly violated the prohibitio­n on mailing chemical abortion drugs by permitting mail order chemical abortions,” those lawmakers wrote in a brief supporting the mifepristo­ne challenge.

Former Attorney General Edwin Meese III and attorney Jay Sekulow, who represente­d Trump during his first impeachmen­t and is now chief counsel at the American Center for Law and Justice, made similar arguments to the court.

Shutting down all abortions?

In addition to the legal action, the conservati­ve Heritage Foundation has put together a policy playbook in case Republican­s retake the White House that includes ending “mail-order abortions in violation of long-standing federal laws.”

“They are really putting a lot into this because it’s a workaround from having to actually pass an abortion ban, which they know they can’t do,” said David S. Cohen, a professor at the Drexel University Thomas R. Kline School of Law.

He considers the Comstock Act the most significant national threat to abortion rights, through either a Supreme Court ruling or a second Trump administra­tion.

Banning abortion drugs from the mail wouldn’t just keep women from directly receiving them, Cohen said. The drugs also could not be shipped to doctors. Neither could medical supplies or instrument­s needed for surgical abortions, he said.

“That interpreta­tion could shut down all abortions,” he said.

Julie Kaye, an attorney with the American Civil Liberties Union’s Reproducti­ve Freedom Project said it’s possible − though it would be surprising − for the court to signal that “this zombie law from the 1880s can be used to ban all abortion without any involvemen­t from Congress.”

In the Justice Department’s briefs to the court, Solicitor General Elizabeth Prelogar reminded the justices that the appeals court decision they are reviewing did not address the Comstock Act.

“And this court,” she added, “should not either.”

 ?? BECK/AFP VIA GETTY IMAGES FILE ROBYN ?? The U.S. Supreme Court is deciding whether the Food and Drug Administra­tion improperly relaxed requiremen­ts on mifepristo­ne, one of the two drugs used in medication abortions for early pregnancie­s.
BECK/AFP VIA GETTY IMAGES FILE ROBYN The U.S. Supreme Court is deciding whether the Food and Drug Administra­tion improperly relaxed requiremen­ts on mifepristo­ne, one of the two drugs used in medication abortions for early pregnancie­s.

Newspapers in English

Newspapers from United States